Exelixis and BMS Unwind Oncology Deals, But Move Forward In Other Areas
This article was originally published in The Pink Sheet Daily
Executive Summary
Four months after BMS walked away from Exelixis's lead drug, the partners scale back more cancer agreements, but BMS licenses two new programs addressing metabolic and inflammatory disease.
You may also be interested in...
Erivedge May Be The Gleevec Of Hedgehog Inhibitors
FDA approval of Curis/Genentech’s hedgehog inhibitor Erivedge validates the class, but basal cell carcinoma is only the ante; cancers exploit hedgehog signaling in a variety of ways yet to be elucidated.
Erivedge BCC Approval Buoys Hedgehog Fans, But Pathway Needs Proof In Other Cancers
FDA approval of Curis/Genentech’s hedgehog inhibitor Erivedge validates the class, but basal cell carcinoma is only the ante; cancers exploit hedgehog signaling in a variety of ways yet to be elucidated.
Exelixis Defends Cancer Drug XL184 After Partner BMS Walks Out
After spending $257 million and pushing into Phase III trials for a rare thyroid cancer, Bristol-Myers Squibb ends its deal. Exelixis CEO George Scangos says: "There is no smoking gun."